Opinion: STAT+: I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer

Enlicitide, an oral PCSK9 inhibitor approved by the FDA, is the first of its kind to lower cholesterol without injections. While it addresses a need for high-risk cardiovascular patients, a cardiologist questions its 'game-changer' status due to uncertainties about its real-world impact.